bcm : reported that Baylor selected as one of three Phase II Zika vaccine trial sites

Volunteers interested in enrolling in the trial should contact the Baylor College of Medicine Vaccine Research Center at 713-798-4912. The other two initial clinical trial sites are Miami and San Juan, Puerto Rico. Most people diagnosed with Zika infection have either no symptoms or only mild ones, such as fever, rash, joint pain and conjunctivitis (red eyes). The Baylor College of Medicine Vaccine Research Center is recruiting volunteers between the ages of 18 and 35 years for the study. Currently there is no licensed vaccine to prevent disease caused by Zika infection, which is mainly transmitted via the bite of infected Aedes aegypti mosquitoes but also can be transmitted sexually.

Indian firm's Zika Virus vaccine 100% efficient in animal trials

A study has indicated that the Bharat Biotech's 'killed Zika virus vaccine' has shown 100 per cent efficacy against mortality and disease in animal studies. Still, the vaccine protects against Zika infection caused by the contemporary Asian strains of Zika virus. As per the study, the firm's 'killed virus vaccine' or 'inactivated vaccine' contains virus that has been grown in culture and then killed using physical or chemical processes. Key results of the study• The vaccine was found to confer 100 per cent protection against infection caused by an Asian Zika virus strain as well as by the African Zika virus strain. The amount of virus present in animals that did not receive the vaccine peaked four days after being infected with either the African or Asian Zika virus strain.

'Indian firm's Zika virus vaccine 100% efficient in animal trials'

The vaccine was found to confer 100% protection against infection caused by an Asian Zika virus strain as well as by the African Zika virus strain. A 'killed virus vaccine' or 'inactivated vaccine' contains virus that has been grown in culture and then killed using physical or chemical processes. more-inThe Hyderabad-based Bharat Biotech's 'killed Zika virus vaccine' using an African strain has shown 100% efficacy against mortality and disease in animal studies, a study has shown. Vaccination protected the animals against Zika virus and disease up to 14 and 20 days after being challenged with the virus. It is important to prove that the vaccine developed with the African strain also protects against Zika infection caused by the contemporary Asian strains of Zika virus.


collected by :Lucy William

To follow all the new news about Health care